2
项与 阿法依伯汀生物类似药(Apotex, Inc.) 相关的临床试验A phase III, randomized, assessor-blinded, active-controlled, multicenterstudy of the efficacy and safety of APO-EPO as compared to Procrit® when given subcutaneously to patients with anemia of chronic kidney disease stage 5D who are currently not on epoetin replacement therapy
A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epogen®/Procrit® when given subcutaneously to patients with anemia and chronic kidney disease not yet on hemodialysis
100 项与 阿法依伯汀生物类似药(Apotex, Inc.) 相关的临床结果
100 项与 阿法依伯汀生物类似药(Apotex, Inc.) 相关的转化医学
100 项与 阿法依伯汀生物类似药(Apotex, Inc.) 相关的专利(医药)
100 项与 阿法依伯汀生物类似药(Apotex, Inc.) 相关的药物交易